Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesPrelude Therapeutics Inc

Prelude Therapeutics Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
3.78 USD 0.02 ( 0.53%)
Last update at 2026-11-11T21:00:00Z
VOLUME
286184
Market Cap
360.71M

Momentum Score

…

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET. The company has collaboration with AbCellera Biologics to discover, develop, and commercialize novel degrader antibody conjugates. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
3.73
Low
4.10
High
52 Week Price Range
0.98
Low
6.83
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
3.76
Dividend Yield
-
Revenue TTM
22.42M
Revenue Per Share
0.27
Gross Profit TTM
22.42M
Debt / Equity
0.26
ROE
-57.73%
Net Debt
-17.47M
ROCE
-112.65%
Diluted EPS TTM
-0.72

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -99.50M -127.17M -121.83M -115.44M -111.69M
Net income -99.50M -127.17M -121.83M -107.34M -110.78M
Selling general administrative 22.41M 28.72M 28.88M 30.65M 26.96M
Selling and marketing expenses - - 1.17M - -
Gross profit 10.43M 7.00M -1.17M - -
Reconciled depreciation 1.71M 1.77M 1.20M 1.32M 0.92M
Ebit -99.50M -127.17M -121.83M -124.86M -114.65M
Ebitda -97.79M -125.40M -120.66M -123.54M -113.73M
Depreciation and amortization 1.71M 1.77M 1.17M 1.32M 0.92M
Operating income -104.57M -139.71M -132.28M -123.54M -113.73M
Other operating expenses 116.71M 146.71M 132.28M 123.54M 113.73M
Interest expense - - - 1.32M 2.04M
Income tax expense - - -0.00M -8.10M -0.92M
Total revenue 12.14M 7.00M 0.00M 0.00M 0.00M
Total operating expenses 115.00M 146.71M 132.28M 123.54M 113.73M
Cost of revenue 1.71M 1.77M 1.17M - -
Total other income expense net 5.07M 12.54M 10.44M 8.10M 2.04M
Net income from continuing ops -99.50M -127.17M -117.40M -115.44M -111.69M
Net income applicable to common shares - - - -115.44M -111.69M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 141.31M 175.51M 277.67M 220.50M 305.10M
Other current assets 2.48M 2.28M 2.65M 2.65M 3.88M
Total liab 72.68M 44.06M 40.58M 25.06M 19.20M
Total stockholder equity 68.64M 131.46M 237.09M 195.44M 285.90M
Other current liab 12.53M 15.21M 0.94M 13.09M 9.62M
Common stock 0.01M 0.01M 0.01M 0.01M 0.01M
Capital stock 0.01M 0.01M 0.01M 0.01M 0.01M
Retained earnings -683.06M -583.56M -456.39M -334.56M -219.12M
Other liab - - - 3.36M -
Other assets - - - 9.42M 4.35M
Cash 35.26M 12.47M 25.29M 30.61M 31.83M
Total current liabilities 52.99M 25.64M 21.83M 21.70M 19.20M
Current deferred revenue 33.73M - 14.82M - -
Net debt -17.47M 5.55M -8.40M -28.77M -30.09M
Short term debt 2.74M 2.70M 1.48M 1.83M 1.74M
Short long term debt total 17.79M 18.02M 16.89M 1.83M 1.74M
Other stockholder equity 751.68M 714.98M 693.25M 531.68M 505.72M
Property plant equipment - - - 6.70M 5.64M
Total current assets 105.69M 135.90M 235.59M 204.38M 295.12M
Net tangible assets - - - 195.44M 285.90M
Short term investments 67.96M 121.14M 207.64M 171.12M 259.40M
Accounts payable 3.98M 7.73M 4.58M 6.78M 7.84M
Accumulated other comprehensive income 0.01M 0.04M 0.22M -1.69M -0.71M
Non currrent assets other 3.35M 4.15M 0.30M 9.42M 4.35M
Non current assets total 35.62M 39.62M 42.08M 16.12M 9.98M
Capital lease obligations 17.79M 18.02M 16.89M 1.83M 1.74M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 53.53M 90.19M -41.03M 81.69M -263.80M
Change to liabilities - - - -0.35M 3.90M
Total cashflows from investing activities 53.46M 90.19M -34.65M 81.69M -263.80M
Net borrowings -0.21M -0.40M 0.00M - -
Total cash from financing activities 24.82M -0.12M 136.40M 0.81M 164.90M
Change to operating activities - - - 1.28M -0.28M
Net income -99.50M -127.17M -121.83M -115.44M -111.69M
Change in cash 21.97M -12.82M -5.31M -1.22M -182.44M
Begin period cash flow 16.52M 29.34M 34.65M 35.87M 218.31M
End period cash flow 38.49M 16.52M 29.34M 34.65M 35.87M
Total cash from operating activities -56.30M -102.89M -107.06M -83.73M -83.53M
Issuance of capital stock 24.88M 0.00M 110.80M 0.00M 161.42M
Depreciation 1.34M 1.77M 1.17M 1.32M 0.92M
Sale purchase of stock - - -0.00M - -
Other cashflows from financing activities -0.02M -0.16M -0.02M 0.43M 3.47M
Change to netincome - - - 29.45M 23.62M
Capital expenditures 0.07M 0.76M 3.51M 3.02M 2.32M
Change in working capital 28.41M 4.22M -10.48M 0.93M 3.62M
Stock based compensation 11.91M 21.34M 25.62M 25.14M 20.93M
Other non cash items 1.53M -3.05M -1.54M 4.31M 1.33M
Free cash flow -56.37M -103.65M -110.58M -86.75M -85.85M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
PRLD
Prelude Therapeutics Inc		 0.02
0.53%		 3.78 - - 16.09 2.73 10.32 -0.54
NVO
Novo Nordisk A/S		 0.41
1.00%		 41.10 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -0.86
0.16%		 547.03 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 43.35
4.73%		 959.41 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Prelude Therapeutics Inc

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET. The company has collaboration with AbCellera Biologics to discover, develop, and commercialize novel degrader antibody conjugates. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

175 Innovation Boulevard, Wilmington, DE, United States, 19805

302 467 1280

https://preludetx.com

79

Name Title Year Born
Dr. Krishna Vaddi D.V.M., Ph.D. Founder, CEO & Director 1966
Dr. Peggy A. Scherle Ph.D. Chief Scientific Officer 1961
Dr. Andrew P. Combs Ph.D. Exec. VP & Head of Chemistry 1966
Dr. Edna Huang M.D. Pres & Chief Medical Officer 1973
Mr. Laurent Chardonnet Chief Financial Officer 1965
Ms. Aimee Crombie Ph.D. Sr. VP and Head of Strategic Planning & Operations NA
Dr. Madhu Pudipeddi Ph.D. Sr. VP of Technical Operations NA
Ms. Michele Porreca M.B.A. Chief People Officer NA
Mr. Naveen Babbar Ph.D. Sr. VP of Translation Medicine NA
Dr. Neelesh Sharma M.D., Ph.D. Sr. VP of Clinical Devel. NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

MAL
CAD 38.85
+13.53%
SOIL
CAD 8.39
+12.02%
QNC
CAD 1.48
+10.45%
TCL-B
CAD 7.26
+9.01%
CLS
CAD 345.53
+8.41%
GSY
CAD 37.75
-16.04%
BYD
CAD 109.98
-11.99%
ELE
CAD 20.12
-11.95%
LAC
CAD 2.39
-11.15%
CFW
CAD 6.51
-10.82%

Equity Sectors*

  • Basic Materials

    -1.75%

  • Communication Services

    +0.20%

  • Consumer Cyclical

    +0.18%

  • Consumer Defensive

    +0.06%

  • Energy

    +1.65%

  • Financial Services

    +0.10%

  • Healthcare

    +1.25%

  • Industrials

    +1.60%

  • Real Estate

    -0.29%

  • Technology

    +2.72%

  • Utilities

    +0.12%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…